{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:46:19Z","timestamp":1790642779676,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jdin.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T18:31:29Z","timestamp":1659897089000},"page":"33-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review"],"prefix":"10.1016","volume":"9","author":[{"given":"Faith A.P.","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabrez","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdin.2022.07.005_bib1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jdin.2022.07.005_bib2","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","volume":"2010","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer","year":"2012","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.33204\/mucosa.607952","article-title":"The toxicity of glucocorticosteroids in autoimmune blister disease","volume":"2","author":"Bilgic","year":"2019","journal-title":"Mucosa"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib5","first-page":"1","article-title":"B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine patterns in patients bullous pemphigoid","volume":"9","author":"Bertani","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jdin.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archderm.144.7.946-a","article-title":"Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid","volume":"144","author":"Bystryn","year":"2008","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","article-title":"Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study","volume":"165","author":"Du-Thanh","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: a retrospective study of thirty-six cases","volume":"34","author":"Bouscarat","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib14","first-page":"309","article-title":"Cyclosporin in the treatment of bullous pemphigoid: preliminary study","volume":"113","author":"Barthelemy","year":"1986","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2022.07.005_bib16","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health. Accessed April 2021. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6146","key":"10.1016\/j.jdin.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","article-title":"Azathioprine plus prednisone in the treatment of pemphigoid","volume":"2","author":"Burton","year":"1978","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoids comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jdv.12155","article-title":"Treatment of bullous pemphigoids with low-dose oral cyclophosphamide: a case series of 20 patients","volume":"28","author":"Gual","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib21","first-page":"205","article-title":"Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases","volume":"76","author":"Schmidt","year":"2005","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.144.5.612","article-title":"A retrospective analysis of patients with bullous pemphigoids treated with methotrexate","volume":"144","author":"Kjellman","year":"2008","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/ejd.2019.3501","article-title":"Methotrexate is a safe and efficient long-term treatment for bullous pemphigoid","volume":"29","author":"Delaumenie","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"10079","key":"10.1016\/j.jdin.2022.07.005_bib26","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomized controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","article-title":"Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter, prospectively randomized study","volume":"3","author":"Rose","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1346-8138.14173","article-title":"Azathioprine monotherapy in autoimmune blistering diseases: a feasible option for mild-to-moderate cases","volume":"45","author":"Kakuta","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09546634.2013.873763","article-title":"Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: a randomized controlled trial","volume":"26","author":"Dastgheib","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","article-title":"Oral\u00a0cyclophosphamide for the treatment of pemphigus vulgaris and foliaceus","volume":"49","author":"Cummins","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2022.07.005_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.12073","article-title":"Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroids in the management of pemphigus vulgaris","volume":"38","author":"Sharma","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2022.07.005_bib34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4103\/ijdvl.IJDVL_625_16","article-title":"Urocytological evaluation of pemphigus patients on long-term cyclophosphamide therapy: a cross-sectional study","volume":"83","author":"Khandpur","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"10.1016\/j.jdin.2022.07.005_bib35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/archderm.136.7.868","article-title":"Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus","volume":"136","author":"Ioannides","year":"2000","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000448028","article-title":"Efficacy of dapsone in the treatment of pemphigus vulgaris: a single-center case study","volume":"232","author":"Baum","year":"2016","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/jid.2008.332","article-title":"UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription","volume":"129","author":"Bashir","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2022.07.005_bib39","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2022.07.005_bib40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1468-3083.2011.04170.x","article-title":"Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study","volume":"26","author":"Ioannides","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/ejd.2011.1611","article-title":"Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris","volume":"22","author":"Baum","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib42","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients","volume":"169","author":"Tran","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib43","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/1346-8138.14732","article-title":"Rituximab therapy for refractory autoimmune bullous diseases: a multicenter, open-label, single-arm, phase 1\/2 study on 10 Japanese patients","volume":"46","author":"Kurihara","year":"2019","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2014.04.040","article-title":"Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents","volume":"71","author":"McCarty","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajd.12422","article-title":"IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects","volume":"57","author":"Svecova","year":"2016","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","article-title":"Is there room for improvement in adverse event reporting in the era of targeted therapies?","volume":"100","author":"Edgerly","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jdin.2022.07.005_bib47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.jdin.2022.07.005_bib48","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"Van Staa","year":"2000","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-induced osteoporosis and osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0606","article-title":"Mechanisms of glucocorticoid-induced myopathy","volume":"197","author":"Schakman","year":"2008","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/dmr.5610040105","article-title":"Effects of glucocorticoids on carbohydrate metabolism","volume":"4","author":"McMahon","year":"1988","journal-title":"Diabetes Metab Rev"},{"issue":"2","key":"10.1016\/j.jdin.2022.07.005_bib52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000441-197603000-00009","article-title":"Effects of glucocorticoids on carbohydrate metabolism","volume":"271","author":"Olefsky","year":"1976","journal-title":"Am J Med Sci"},{"issue":"suppl 1","key":"10.1016\/j.jdin.2022.07.005_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000314213","article-title":"Pathophysiology of dyslipidemia in Cushing\u2019s syndrome","volume":"92","author":"Arnaldi","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"15","key":"10.1016\/j.jdin.2022.07.005_bib54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jdin.2022.07.005_bib55","first-page":"81","article-title":"Management and treatment with systemic glucocorticoids","volume":"8","author":"Werth","year":"1993","journal-title":"Adv Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.07.005_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib57","first-page":"17","article-title":"Mood and cognitive changes during systemic corticosteroid therapy","volume":"3","author":"Brown","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jdin.2022.07.005_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0002-9394(65)95015-4","article-title":"Corticosteroids and functions in the anterior segment of the eye","volume":"59","author":"Miller","year":"1965","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract","volume":"23","author":"James","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jdin.2022.07.005_bib60","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0025-7125(16)32228-3","article-title":"Corticosteroids and infectious diseases","volume":"57","author":"Dale","year":"1973","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jdin.2022.07.005_bib61","year":"2011"},{"key":"10.1016\/j.jdin.2022.07.005_bib62","year":"2013"},{"key":"10.1016\/j.jdin.2022.07.005_bib63","year":"2012"},{"key":"10.1016\/j.jdin.2022.07.005_bib64","series-title":"Aczone (dapsone). Package insert","year":"2018"},{"key":"10.1016\/j.jdin.2022.07.005_bib65","year":"2017"},{"key":"10.1016\/j.jdin.2022.07.005_bib66","year":"2019"},{"key":"10.1016\/j.jdin.2022.07.005_bib67","year":"2018"},{"key":"10.1016\/j.jdin.2022.07.005_bib68","series-title":"Niaspan (niacin extended-release tablets). Package insert","year":"2015"},{"key":"10.1016\/j.jdin.2022.07.005_bib69","year":"2012"},{"key":"10.1016\/j.jdin.2022.07.005_bib70","year":"2010"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328722000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328722000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:00:10Z","timestamp":1762981210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328722000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":71,"alternative-id":["S2666328722000979"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2022.07.005","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}